Biocon Biologics receives FDA approval for biosimilar YESINTEK
The biosimilar Ustekinumab-kfce is set for commercialisation in the US by February 2025 under a licensing agreement with Janssen
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
biosimilar
Biocon Biologics report explores pathways to increase biosimilar adoption in low- and middle-income…
Biocon Biologics' study identifies six policy recommendations to improve access to biosimilars in LMICs, addressing healthcare…
USFDA grants approval of Bkemv to Amgen
Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases
USV and Biogenomics launches Insuquick
Insuquick is a “Make in India” product and is available in all metros, and tier I/II cities
Biocon Biologics successfully integrates acquired biosimilars business across 120 countries
Over 10 emerging markets along with Japan, Australia and New Zealand have transitioned in this final phase of the integration of…
USV, Biogenomics launch INSUQUICK, biosimilar Insulin Aspart for diabetes treatment
Insuquick will be available in cartridges, vials, and prefilled disposable pens
EMA accepts Intas Pharma’s MAA for DMB-3115
herapeutic equivalence and safety confirmed between DMB-3115 and Stelara in global phase III
Dr Reddy’s completes Phase I study of DRL_TC, a tocilizumab biosimilar candidate
This Phase I study used an intravenous (IV) formulation to evaluate the pharmacokinetic equivalence, safety and immunogenicity of…
Biocon Biologics, Viatris get EC approval for biosimilar Bevacizumab
Abevmy 100 and 400 mg is approved for the treatment of metastatic colorectal carcinoma, metastatic breast cancer, non small-cell…
USFDA defers action on BLA for Avastin biosimilar, notifies Biocon Biologics, Mylan
To complete the application, the agency noted that an inspection of the manufacturing facility is required as a part of the…